All stock lists
Unlock the score
Edap Tms Sa (NASDAQ:EDAP)
FR · Delayed Price · Currency is USD
Also listed: FOCLHealthcare · Medical - Specialties
4.75-0.03 (-0.52%)
Market cap
$178M
Insider Score
Health Score
Analyst consensus
Listed since
Aug 1, 1997
Website
Insider Score
/ 100
EDAP Insider Score
EDAP TMS SA has a live Insider Score.
Scored on 8 qualifying trades from 8 insiders in the last 90 days.
Financial Health Score
Weak
From EDAP’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $62.9M
- Net income
- -$38.9M
- Net margin
- -61.8%
Leverage—
Not enough balance-sheet detail to judge the debt load.
- Total debt
- $41.7M
- Cash
- $11.8M
Liquidity15 / 20
Comfortably covers what is due within a year.
- Current assets
- $59.0M
- Current liabilities
- $36.8M
- Current ratio
- 1.60
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$13.1M
- Free cash flow
- -$18.0M
- FCF margin
- -28.6%
Dilution & runway5 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 37.5M
- Share growth (1y)
- 0.2%
- Cash runway
- 11 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
EDAP Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 6.92 M | 17.88 M | 21.86 M | 16.22 M | 16.04 M | 13.56 M |
| Revenue Growth (YoY) | -56.87 % | 31.85 % | 7.61 % | 23.82 % | 1.60 % | -9.05 % |
| Cost of Revenue | 1.79 M | 9.70 M | 12.55 M | 9.24 M | 9.22 M | 7.86 M |
| Gross Profit | 5.12 M | 8.18 M | 9.31 M | 6.98 M | 6.82 M | 5.70 M |
| SG&A Expense | 25.91 M | -1.33 M | 13.22 M | 10.30 M | 0.00 | 0.00 |
| R&D Expense | 2.18 M | 2.61 M | 2.11 M | 2.44 M | 2.21 M | 2.46 M |
| Operating Expenses | 28.08 M | 15.57 M | 15.32 M | 12.73 M | 12.59 M | 11.69 M |
| Operating Income | -8.02 M | -7.39 M | -6.02 M | -5.76 M | -5.77 M | -6.00 M |
| Pretax Income | -14.38 M | -8.97 M | -9.38 M | -5.74 M | -5.51 M | -6.94 M |
| Tax Provision | 7.99 K | 145.53 K | 64.95 K | 120.37 K | 93.00 K | 137.00 K |
| Net Income | -14.45 M | -9.12 M | -9.45 M | -5.86 M | -5.60 M | -7.07 M |
| EPS (Basic) | -0.39 | -0.24 | -0.25 | -0.13 | -0.15 | -0.19 |
| EPS (Diluted) | -0.39 | -0.24 | -0.25 | -0.13 | -0.15 | -0.19 |
| Shares Outstanding | 37.48 M | 37.48 M | 37.45 M | 37.44 M | 37.39 M | 37.39 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.